Frequencies of tetramer+ T cells specific for the wild-type sequence p53264-272 peptide in the circulation of patients with head and neck cancer

Cancer Research

Volumn 62, Issue 12, 2002, Pages 3521-3529

  Hoffmann, Thomas K ^a   Donnenberg, Albert D ^a,b,c   Finkelstein, Sydney D ^b   Donnenberg, Vera S ^a,b   Friebe Hoffmann, Ulrike ^c   Myers, Eugene N ^b   Appella, Ettore ^d   DeLeo, Albert B ^a,b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; EPITOPE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TETRAMER;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MEMORY CELL; METASTASIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HEAD AND NECK NEOPLASMS; HIV-1 REVERSE TRANSCRIPTASE; HLA-A2 ANTIGEN; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC MEMORY; ONCOGENE PROTEINS, VIRAL; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; VIRAL MATRIX PROTEINS;

EID: 0037096905     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. p53 mutations in human cancers
2. Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation
3. p53 overexpression in head and neck squamous cell carcinoma: Review of the literature
4. Structure and function of the p53 tumor suppressor gene: Clues and rational cancer therapeutic strategies
5. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors
6. The humoral response to the tumor-suppressor gene-product p53 in human cancer: Implications for the diagnosis and therapy
7. p53-based immunotherapy of cancer
8. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells
9. 264-272 peptide in cancer patients-implications for immunoselection of epitope-loss variants
10. Human papilloma virus and head and neck cancer: Epidemiology and molecular biology
11. Phenotypic analysis of antigen-specific T lymphocytes
12. Ligand recognition by α β T cell receptors
13. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex
14. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations
15. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
16. Flow-cytometric determination of peptide-class-I complex formation. Identification of p53 peptides that bind to HLA-A2
17. Prediction of biologic aggressiveness in colorectal cancer by p53/K-ras-2 topographic genotyping
18. Control of lymphocyte recirculation in man
19. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope
20. p53 mutation as a prognostic marker in advanced laryngeal carcinoma
21. MDM2-arbiter of p53's destruction
22. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma
23. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
24. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA-A0201 peptide consensus motif
25. Clinical cancer vaccine trials
26. The role of Fas/FasL in immunosuppression induced by human tumors
27. Targeting p53 as a general tumor antigen
28. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas
29. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
30. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
31. Tumor eradication by wild type p53 specific cytotoxic T lymphocytes
32. Human papillomavirus infection in "young" versus "old" patients with squamous cell carcinoma of the head and neck
33. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
34. The use of HLA-A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire
35. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: Relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides
36. p53, a potential target for tumor-directed T cells
37. p53 expressions: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma
38. 264-272 epitope
39. Targeting p53 for adoptive T-cell immunotherapy